Opaleye Management Inc. Vaxcyte, Inc. Transaction History

Opaleye Management Inc.

$390 Million
Q2 2024

A detailed history of Opaleye Management Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 85,000 shares of PCVX stock, worth $9.48 Million. This represents 1.64% of its overall portfolio holdings.

Number of Shares

85,000

Previous 85,000 -0.0%

Holding current value

$9.48 Million

Previous $5.81 Million 10.54%

% of portfolio

1.64%

Previous 1.41%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $298,950 - $405,250	-5,000 Reduced 5.56%	85,000 $5.81 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $4 Million - $4.62 Million	-87,000 Reduced 49.15%	90,000 $4.59 Million
Q4 2022 Feb 10, 2023	SELL	$20.58 - $47.95 $267,540 - $623,350	-13,000 Reduced 6.84%	177,000 $8.49 Million
Q2 2022 Aug 15, 2022	SELL	$17.68 - $26.58 $371,280 - $558,180	-21,000 Reduced 9.95%	190,000 $4.13 Million
Q1 2022 May 16, 2022	SELL	$17.46 - $26.36 $1.83 Million - $2.76 Million	-104,800 Reduced 33.19%	211,000 $5.1 Million
Q4 2021 Feb 14, 2022	SELL	$19.32 - $26.45 $726,432 - $994,520	-37,600 Reduced 10.64%	315,800 $7.51 Million
Q3 2021 Nov 16, 2021	SELL	$20.26 - $26.97 $89,144 - $118,668	-4,400 Reduced 1.23%	353,400 $8.97 Million
Q1 2021 May 18, 2021	BUY	$18.66 - $29.16 $421,716 - $659,016	22,600 Added 6.74%	357,800 $7.07 Million
Q4 2020 Feb 12, 2021	BUY	$26.57 - $51.74 $589,854 - $1.15 Million	22,200 Added 7.09%	335,200 $8.91 Million
Q3 2020 Nov 16, 2020	BUY	$26.5 - $55.4 $8.29 Million - $17.3 Million	313,000 New	313,000 $15.5 Million

Others Institutions Holding PCVX

# of Institutions

286

Shares Held

110M

Call Options Held

248K

Put Options Held

109K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $6.62B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.

Account

Opaleye Management Inc. Vaxcyte, Inc. Transaction History